

Dear Prof. Li Ma,

We sincerely thank the editor and all reviewers for their valuable feedback that we have used to improve the quality of our manuscript. We have provided the English Language Certificate issued by *editage* and the single PowerPoint file consisted of figures.

Changes/additions to the manuscript are given in yellow highlight. The reviewer comments and our response are listed as follows.

Round 1

Reviewer #1:

We feel great thanks for your professional review work on our article. As you are concerned, there are several problems that need to be addressed. According to your nice suggestions, we have made extensive corrections to our previous draft, the detailed responses are listed:

No.	Location	Common issues and comments
1	Abstract	Issue: The abstract should be one paragraph with 150-250 words. It should emphasize the analytics model used in the study, the data, the results, and the novelty of the proposed approach. You need to expand the acronyms in the abstract upon the first use. Minimize acronyms. Stick to the point and make that point power- fully. Tell the reader what your research is about, what methods you used, and what you found. Please revise your abstract accordingly and make sure there are no English or grammar problems in the abstract. Please edit your abstract Grammar: There are a grammatical errors. This must be taken care of and addressed. Comment: We sincerely thank the reviewer for careful reading. We have rewritten the abstract in the revised manuscript. And we have tried our best to polish the language.
2	Main text	Comment: We sincerely thank the reviewer for careful editing. We have corrected the errors in the revised manuscript.

Reviewer #2:

Thank you for your suggestion, we have made revisions to our previous draft, and the detailed responses are listed:

No.	Location	Common issues and comments
1		Issue: A linguistic revision is also required. Comment: We have tried our best to improve the manuscript and made some changes to the manuscript. Meanwhile, we have provided the English Language Certificate issued by a professional English language editing company.
2	Abstract	Issue: The background of the changing scenario of medical treatment in colorectal cancer should be better discussed, and some recent papers regarding this topic should be included (PMID: 35031442; PMID: 32762027; PMID: 32684988; PMID: 37535194)

		Comment: We think this is an excellent suggestion and have added the background about the utility of immunotherapy for dMMR colon cancer.
--	--	---

Round 2

Dear Editor Yan,

We sincerely thank the editor and all reviewers for their valuable feedback that we have used to improve the quality of our manuscript. Changes/additions to the manuscript are given in yellow highlight. The reviewer comments and our response are listed as follows.

Reviewer:

We feel great thanks for your professional review work on our article. As you are concerned, there are several problems that need to be addressed. According to your nice suggestions, we have made extensive corrections to our previous draft, the detailed responses are listed:

No.	Location	Common issue and comment
1	Abstract	<p>Issue: The background of the changing scenario of medical treatment in colorectal cancer should be better discussed, and some recent papers regarding this topic should be included (PMID: 35031442; PMID: 32762027; PMID: 32684988; PMID: 37535194). The authors have not revised accordingly.</p> <p>Comment: We sincerely thank the reviewer for careful reading. However, the papers that reviewer purposed were not related with our manuscript:</p> <p>PMID: 35031442 The MOUSEION-01 aimed to investigate the impact of gender on the efficacy of immune checkpoint inhibitors in cancer patients, which didn't included trial of colorectal cancer.</p> <p> > Crit Rev Oncol Hematol. 2022 Feb;170:103596. doi: 10.1016/j.critrevonc.2022.103596. Epub 2022 Jan 12.</p> <p>The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study</p> <p>Matteo Santoni ¹, Alessandro Rizzo ², Veronica Mollica ², Marc R Matrana ³, Matteo Rosellini ², Luca Faloppi ¹, Andrea Marchetti ², Nicola Battelli ¹, Francesco Massari ⁴</p> <p>Affiliations + expand PMID: 35031442 DOI: 10.1016/j.critrevonc.2022.103596</p>

PMID: 32762027 This paper was a letter about chemotherapy feasible in liver transplantation for colorectal cancer liver metastases, which wasn't associated with our manuscript.

16.2 1区 > [Cancer Commun \(Lond\)](#). 2020 Sep;40(9):461-464. doi: 10.1002/cac2.12072. Epub 2020 Aug 6.

Is post-transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?

[Giovanni Brandi](#)¹, [Angela Dalia Ricci](#)¹, [Alessandro Rizzo](#)¹, [Chiara Zanfi](#)², [Simona Tavorari](#)³, [Andrea Palloni](#)¹, [Stefania De Lorenzo](#)¹, [Matteo Ravaioli](#)², [Matteo Cescon](#)²

Affiliations + expand

PMID: 32762027 PMCID: [PMC7494063](#) DOI: [10.1002/cac2.12072](#)

PMID: 32684988 This paper aimed to investigate the dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug

4.9 2区 > [Ther Adv Med Oncol](#). 2020 Jul 7:12:1758835920936932. doi: 10.1177/1758835920936932. eCollection 2020.

Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis

[Alessandro Rizzo](#)¹, [Margherita Nannini](#)², [Marco Novelli](#)³, [Angela Dalia Ricci](#)¹, [Valerio Di Scioscio](#)³, [Maria Abbondanza Pantaleo](#)¹

Affiliations + expand

PMID: 32684988 PMCID: [PMC7343359](#) DOI: [10.1177/1758835920936932](#)

events in cancer patients. However, regorafenib wasn't immunotherapy. Thus, adding this paper in our manuscript wasn't suitable.

	<p>PMID: 37535194 The MOUSEION-06 study investigated the the impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients, which wasn't related with immunotherapy for deficient mismatch repair locally unresectable colon cancer.</p> <p>4.6 3x > Clin Exp Med. 2023 Aug 3. doi: 10.1007/s10238-023-01159-1. Online ahead of print.</p> <p>The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study</p> <p>Veronica Mollica ^{1 2}, Alessandro Rizzo ³, Andrea Marchetti ^{1 2}, Valentina Tateo ^{1 2}, Elisa Tassinari ^{1 2}, Matteo Rosellini ^{1 2}, Raffaella Massafra ⁴, Matteo Santoni ^{# 5}, Francesco Massari ^{# 1 2}</p> <p>Affiliations + expand</p> <p>PMID: 37535194 DOI: 10.1007/s10238-023-01159-1</p> <p>Meanwhile, we have polished our manuscript by a professional English language editing company and provided the certificate.</p>
--	--